A phase I, multi-centre, open-label, dose selection study to assess the safety and tolerability of AZD2171 (Recentin) [cediranib] in combination with etoposide and cisplatin (EP) as first line therapy for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

Trial Profile

A phase I, multi-centre, open-label, dose selection study to assess the safety and tolerability of AZD2171 (Recentin) [cediranib] in combination with etoposide and cisplatin (EP) as first line therapy for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Cediranib (Primary) ; Cisplatin; Etoposide
  • Indications Lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Sep 2011 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 10 Mar 2011 Planned end date changed from 1 Mar 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Planned End Date changed from 1 Jan 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top